Jennifer L Beebe-Dimmer1,2, Kimberly A Zuhlke3, Anna M Johnson3,4, Daniel Liesman3,4, Kathleen A Cooney5. 1. Population Studies and Disparities Research Program, Karmanos Cancer Institute, Detroit, Michigan, 48201. 2. Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan, 48201. 3. University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109. 4. Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, 48109. 5. Department of Internal Medicine, Cancer Institute, University of Utah School of Medicine and the Huntsman Cancer, Salt Lake City, Utah, 84132.
Abstract
BACKGROUND: African Americans have both a higher incidence of prostate cancer and greater disease-specific mortality compared with non-Hispanic whites. Historically, the investigation of the contribution of rare genetic variants to prostate cancer in African American men has been hampered by low participation in large genetic studies, particularly those focused on early-onset and familial disease. METHODS: We sequenced 160 genes purported to be involved in carcinogenic pathways in germline DNA samples collected from 96 African American men diagnosed with early-onset prostate cancer (≤55 years at diagnosis). REVEL software was used to determine the pathogenic potential of observed missense variants. RESULTS: We observed three protein-truncating mutations, one in BRCA2 and two in BRIP1 in three African American men diagnosed with early-onset prostate cancer. Furthermore, we observed five rare, mostly private, missense variants among four genes (BRCA1, BRCA2, PMS2, and ATM) that were predicted to be deleterious and hence likely pathogenic in our patient sample. CONCLUSIONS: Protein-truncating mutations in BRCA2 and BRIP1 were discovered in African American men diagnosed with early-onset prostate cancer. Further study is necessary to determine the role of rare, missense variants to prostate cancer incidence, and progression in this group of high-risk men.
BACKGROUND: African Americans have both a higher incidence of prostate cancer and greater disease-specific mortality compared with non-Hispanic whites. Historically, the investigation of the contribution of rare genetic variants to prostate cancer in African American men has been hampered by low participation in large genetic studies, particularly those focused on early-onset and familial disease. METHODS: We sequenced 160 genes purported to be involved in carcinogenic pathways in germline DNA samples collected from 96 African American men diagnosed with early-onset prostate cancer (≤55 years at diagnosis). REVEL software was used to determine the pathogenic potential of observed missense variants. RESULTS: We observed three protein-truncating mutations, one in BRCA2 and two in BRIP1 in three African American men diagnosed with early-onset prostate cancer. Furthermore, we observed five rare, mostly private, missense variants among four genes (BRCA1, BRCA2, PMS2, and ATM) that were predicted to be deleterious and hence likely pathogenic in our patient sample. CONCLUSIONS: Protein-truncating mutations in BRCA2 and BRIP1 were discovered in African American men diagnosed with early-onset prostate cancer. Further study is necessary to determine the role of rare, missense variants to prostate cancer incidence, and progression in this group of high-risk men.
Authors: Daniel J Lee; Ryan Hausler; Anh N Le; Gregory Kelly; Jacquelyn Powers; James Ding; Emily Feld; Heena Desai; Casey Morrison; Abigail Doucette; Peter Gabriel; Regeneron Genetics Center; Renae L Judy; Joellen Weaver; Rachel Kember; Scott M Damrauer; Daniel J Rader; Susan M Domchek; Vivek Narayan; Lauren E Schwartz; Kara N Maxwell Journal: Eur Urol Date: 2021-10-25 Impact factor: 24.267
Authors: Michelle S Kim; Daphne Naidoo; Ujani Hazra; Melanie H Quiver; Wenlong C Chen; Corinne N Simonti; Paidamoyo Kachambwa; Maxine Harlemon; Ilir Agalliu; Shakuntala Baichoo; Pedro Fernandez; Ann W Hsing; Mohamed Jalloh; Serigne M Gueye; Lamine Niang; Halimatou Diop; Medina Ndoye; Nana Yaa Snyper; Ben Adusei; James E Mensah; Afua O D Abrahams; Richard Biritwum; Andrew A Adjei; Akindele O Adebiyi; Olayiwola Shittu; Olufemi Ogunbiyi; Sikiru Adebayo; Oseremen I Aisuodionoe-Shadrach; Maxwell M Nwegbu; Hafees O Ajibola; Olabode P Oluwole; Mustapha A Jamda; Elvira Singh; Audrey Pentz; Maureen Joffe; Burcu F Darst; David V Conti; Christopher A Haiman; Petrus V Spies; André van der Merwe; Thomas E Rohan; Judith Jacobson; Alfred I Neugut; Jo McBride; Caroline Andrews; Lindsay N Petersen; Timothy R Rebbeck; Joseph Lachance Journal: Genome Biol Date: 2022-09-13 Impact factor: 17.906
Authors: Ninad Oak; Andrew D Cherniack; R Jay Mashl; Fred R Hirsch; Li Ding; Rameen Beroukhim; Zeynep H Gümüş; Sharon E Plon; Kuan-Lin Huang Journal: Genome Med Date: 2020-05-29 Impact factor: 15.266